Exercise and ER-Positive Breast Cancer: What PFS Data Show

Exercise may matter after an ER-positive breast cancer diagnosis, not only before it. In a 2024 prospective cohort of women with advanced hormone receptor-positive, HER2-negative breast cancer, participants who met a standard physical-activity threshold had approximately 16% better progression-free survival and fewer treatment adverse events while receiving everolimus plus exemestane. That is a clinically interesting association. It is not yet proof that exercise caused either result.

The distinction matters. Cancer patients who can stay active may begin treatment healthier, have fewer comorbidities, or differ in ways a questionnaire cannot capture. Still, the finding fits larger evidence on breast cancer prognosis, postmenopausal hormones, body fat, and physical activity. Exercise belongs in oncology care; it does not belong in place of oncology care.

A progression-free survival signal in advanced ER-positive disease

A 2024 BRAWO prospective cohort study followed 1,440 postmenopausal patients treated at 341 German oncology centers between 2012 and 2017. All had advanced HR-positive, HER2-negative breast cancer and were receiving second-line everolimus plus exemestane. Participants reported leisure-time activity with the validated Godin Leisure-Time Exercise Questionnaire.

Researchers classified 332 patients (23%) as active using a leisure-score threshold of 24 or higher, which corresponds to the World Health Organization target of at least 150 minutes a week of moderate-intensity activity. The other 1,108 patients did not meet that threshold. The active group had approximately 16% better progression-free survival and reported fewer adverse events from treatment.

Progression-free survival measures the time before cancer progresses or a patient dies; it is not the same endpoint as overall survival. The cohort also does not establish an absolute gain in months, a precise exercise dose-response curve, or a causal effect. Only 23% of participants met the active threshold, which limits finer comparisons across activity levels.

The adverse-event finding deserves attention because treatment tolerability can shape whether patients can remain on therapy. But it has the same limitation as the PFS result: this was an observational comparison of self-reported activity, not random assignment to an exercise program.

For a patient receiving endocrine-targeted therapy, the reasonable conclusion is practical: activity may be a useful adjunct to treatment, but it cannot substitute for treatment.

Why the signal fits the rest of the evidence

The BRAWO result does not sit alone. A 2022 systematic review and meta-analysis of post-diagnosis recreational activity found that physical activity after breast cancer diagnosis was associated with better prognosis overall. That broader literature covers breast cancer populations rather than the specific advanced, postmenopausal, second-line treatment setting in BRAWO. It supports the direction of the association; it does not confirm the same PFS effect in every subtype or treatment setting.

Prevention studies point toward a particularly relevant pattern in postmenopausal hormone-sensitive disease. A 2024 Nurses' Health Studies analysis included 187,278 women, 12,785 incident breast cancer cases, and as much as 30 years of follow-up. Recreational activity was assessed in MET-hours per week, using fewer than 3 MET-hours per week as the reference category. Higher activity was inversely associated with postmenopausal ER-positive/PR-positive breast cancer incidence.

That association was weaker and less consistent for premenopausal disease and ER-negative/PR-negative tumors. Exercise has broad health benefits in many settings, but the evidence does not justify treating every breast cancer subtype as biologically interchangeable. An 2024 umbrella review likewise identified physical activity as a consistently supported modifiable factor for breast cancer risk across meta-analyses.

The postmenopausal estrogen pathway is plausible, not fully proven

After menopause, adipose tissue becomes the main site where aromatase converts androgens into estrogens. That makes body composition relevant to ER-positive breast cancer biology. A review of ER-positive breast cancer in postmenopausal women describes how excess adipose tissue can raise estrogen and testosterone, lower sex hormone-binding globulin (SHBG), and increase bioavailable estrogen that can activate ERα. ERα drives roughly 75% of breast cancers.

There may be a second route. Adipose tissue releases leptin, TNF-α, IL-6, and IL-1β. The review describes evidence that these inflammatory signals can activate ERα through phosphorylation at serine 305 via IKKβ, even without estrogen binding, a possible contributor to endocrine resistance. Reducing fat mass and inflammatory signaling could therefore affect ER-positive tumors through more than one pathway.

That model has human support at the hormone level. In a 2022 randomized trial, postmenopausal breast cancer survivors were assigned to exercise alone, diet alone, exercise plus diet, or control conditions. The trial tested changes in sex steroid hormones rather than cancer progression or survival. Exercise changed estrogens, testosterone, and SHBG in the expected direction, consistent with the adipose-aromatase hypothesis.

Yet diet alone produced hormone changes in the same direction. A separate randomized trial of synbiotic supplementation plus a weight-loss diet also improved IGF-1 and sex-hormone measures in overweight and obese postmenopausal breast cancer survivors. That result complicates any claim that the hormonal effect belongs uniquely to exercise. Fat loss and metabolic change may explain part of the benefit; current disease-endpoint evidence cannot separate that contribution from exercise-specific effects.

Physical activity may also matter beyond weight. A Women's Health Initiative observational analysis linked prolonged sitting and low activity with higher circulating estrogens and androgens in postmenopausal women, independently of body weight. This supports the idea that movement and sedentary time relate to hormones, but it remains observational. Animal findings that training may alter the ERβ-to-ERα ratio are even further from a clinical prescription; human confirmation in patients receiving endocrine therapy is absent.

What the evidence can and cannot prescribe

No completed randomized trial has tested structured exercise with progression-free survival or overall survival as the primary endpoint in advanced ER-positive breast cancer. A 2024 systematic review and network meta-analysis found that lifestyle interventions may reduce recurrence risk in breast cancer survivors, but uncertainty remains about the best intervention type and the size of any disease-outcome effect because high-quality randomized evidence is limited.

BRAWO's active participants may have had better baseline performance status, fewer illnesses, or more favorable prior treatment histories. Self-reported activity also introduces measurement error. The study applies most directly to postmenopausal patients with advanced HR-positive, HER2-negative disease receiving second-line everolimus plus exemestane. It does not establish the same PFS benefit for early-stage disease, first-line endocrine therapy, other treatment histories, or premenopausal women.

The practical verdict

For postmenopausal women with ER-positive breast cancer, working toward at least 150 minutes a week of moderate activity is a sensible clinical target when their oncology team considers it safe. The target matches the activity threshold associated with better PFS and fewer adverse events in BRAWO, while larger observational and mechanistic evidence makes the association biologically credible.

Patients should individualize the plan around fatigue, bone health, neuropathy, metastases, surgery, and treatment effects. A walking program, cycling, resistance training, or supervised cancer-exercise program may all be workable options; the current evidence cannot name one superior regimen for advanced ER-positive disease. The useful claim is narrower and stronger: exercise is a plausible complementary lever with measurable associations in this population, while endocrine-targeted therapy remains the treatment doing the indispensable job.